Why the study?
The effects of dual deficiency of ACE2 and Mas receptor on Ang II-induced hypertensive nephropathy remained unexplored.
Does dual deficiency of ACE2 and Mas receptor exacerbate Ang II-induced hypertension and hypertensive nephropathy in mice?
Does dual deficiency of ACE2 and Mas receptor exacerbate Ang II-induced hypertension and hypertensive nephropathy in mice?
Answers are grounded in this paper and cite their sources.
Dual deficiency of ACE2 and Mas receptor additively exacerbates Ang II-induced hypertension and hypertensive nephropathy in mice, suggesting the ACE2/Ang1-7/Mas axis as a potential therapeutic target.
Angiotensin-converting enzyme-2 (ACE2) and Mas receptor are the major components of the ACE2/Ang 1-7/Mas axis and have been shown to play a protective role in hypertension and hypertensive nephropathy individually. However, the effects of dual deficiency of ACE2 and Mas (ACE2/Mas) on Ang II-induced hypertensive nephropathy remain unexplored, which was investigated in this study in a mouse model of hypertension induced in either ACE2 knockout (KO) or Mas KO mice and in double ACE2/Mas KO mice by subcutaneously chronic infusion of Ang II. Compared with wild-type (WT) animals, mice lacking either ACE2 or Mas significantly increased blood pressure over 7-28 days following a chronic Ang II infusion (P < .001), which was further exacerbated in double ACE2/Mas KO mice (P < .001). Furthermore, compared to a single ACE2 or Mas KO mice, mice lacking ACE2/Mas developed more severe renal injury including higher levels of serum creatinine and a further reduction in creatinine clearance, and progressive renal inflammation and fibrosis. Mechanistically, worsen hypertensive nephropathy in double ACE2/Mas KO mice was associated with markedly enhanced AT1-ERK1/2-Smad3 and NF-κB signalling, thereby promoting renal fibrosis and renal inflammation in the hypertensive kidney. In conclusion, ACE2 and Mas play an additive protective role in Ang II-induced hypertension and hypertensive nephropathy. Thus, restoring the ACE2/Ang1-7/Mas axis may represent a novel therapy for hypertension and hypertensive nephropathy.
No takes yet. Share an insight, caveat, or question.
Ni et al. (2020) studied Hypertension and hypertensive nephropathy. Dual deficiency of ACE2 and Mas (ACE2/Mas KO) with Ang II infusion vs. Wild-type (WT) animals and single ACE2 or Mas KO mice was evaluated on Blood pressure and renal injury (p=<.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: